



Albireo to Present at Investor Conferences in June

May 29, 2019

BOSTON, May 29, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the following investor conferences in June:

2019 Jefferies Global Healthcare Conference

Location: New York City

Presentation date / time: Tuesday, June 4, 8 a.m. EDT

William Blair 39th Annual Growth Stock Conference

Location: Chicago

Presentation date / time: Thursday, June 6, 12:40 p.m. CDT

Live audio webcasts of both conference presentations will be accessible from the Media & Investors page of Albireo's website, ir.albireopharma.com. To ensure a timely connection to the webcasts, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcasts will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo's website for at least two weeks following each event.

About Albireo

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo's lead product candidate, odevixibat (A4250), is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis (PFIC). Albireo's clinical pipeline also includes two Phase 2 product candidates. Albireo's elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. The *Boston Business Journal* named Albireo one of the 2019 Best Places to Work in Massachusetts. For more information on Albireo, please visit www.albireopharma.com.

Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC, 212-915-2568

Media Contact: Heather Anderson, 6 Degrees, 980-938-0260, handerson@6degreespr.com

Source: Albireo Pharma, Inc.



Source: Albireo Pharma, Inc.